Clay Siegall Leads Seattle Genetics in Providing Targeted Therapies for Patients

Clay Siegall Leads Seattle Genetics in Providing Targeted Therapies for Patients

Seattle Genetics was established to develop and commercialize innovative and empoweredantibody-based therapies in order to treat cancer. This company is centrally situated in Bothell, Washington and is the industry leader of anti-body drug conjugates, a technology created to harness the eradication of cancer cells by killing the agents. These antibody-drug conjugates are made to kill targeted cells thereby reducing the toxic effects of conventional chemotherapy. Simultaneously, the therapy should enhance antitumor activity.

Background

The foundation of Seattle Genetics rests with Clay Siegall. He is also the CEO and has overseen the management of the firm since it was established. He is an alumnus of The University of Maryland where he attained his bachelor of science in zoology. This was followed by a course in genetics from the prestigious George Washington University.

Targeted Therapies

Since the establishment of Seattle Genetics, Seagall has guided the firm towards the leading apex of targeted therapies in creating the first FDA-approved drug conjugate. Today, it has earned multiple approvals from different healthcare practises. Under his leadership, the company has also developed a robust pipeline of drugs with a string of major partnerships from drug manufacturers like Pfizer, Bayer, and others.

Leadership Roles

Moreover, Clay Siegall has grown Seattle Genetics by making it the hub of researchers. The organization will likely launch more drugs in the next three years. With this expanding list of drugs, it is going to be possible for the company to partner with more pharmaceuticals in order to increase the potential indications for its existence. Other than that, the firm’s flagship product called Adcetris is commercially available in over 65 countries including Japan and the U.S.

Observation

Siegall believes that there should be newer treatment methods for cancer. And unlike in the past where there are systemic chemotherapies, the future should be dedicated to finding instrumental treatment methods and therapies. The older therapies should be replaced with the new ones. To expand its clinical therapies, the organization is conducting clinical developmental programs to evaluate therapeutic potentials in earlier stages of its approved indications. Clay Siegall continues to cheerlead the development of drugs and therapies.